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a  b  s t r a  c t
Due  to  their recognised  properties  of biocompatibility,  biodegradability and  sustainability, chitosan
nanocarriers  have  been successfully  used  as  new delivery  systems.  In  this  work,  nanoparticles  combining
chitosan  and lignosulfonates were  developed for  the  first  time  for cosmetic  and  biomedical  applications.
The ability of lignosulfonates to act  as  a counter polyion  for stabilisation  of  chitosan  particles,  gener-
ated  using high  intensity  ultrasound, was investigated. Several  conditions for particles  preparation  were
tested and optimised and the  resulting nanoparticles  were  comprehensively  characterised  by measuring
particle size,  zeta  potential and polydispersity  index. The  pH of chitosan  solution,  sonication  time  and
the  presence of an adequate  surfactant,  poloxamer 407, were determinant  factors  on the  development
of smaller  particles  with  low  polydispersity index  (an  average particle  size of  230  nm  was  obtained  at
pH 5  after 8  min of sonication). The beneficial effects of  lignosulfonates complex on chitosan  nanoparti-
cles were  further  characterised.  Greater stability  to lysozyme  degradation,  biocompatibility  with  human
cells and antimicrobial activity  was found  upon  lignosulfonates  incorporation into  chitosan  nanoparti-
cles. Furthermore,  these particles were  able  to  incorporate  a  hydrophilic  model protein – RNase A. A
burst  release was  observed  when nanoparticles  were loaded with low  amount of protein while with  high
protein  content, a  sustained release was  found,  suggesting  that  the  protein  cargo  maybe loaded both  at
the surface  as in  the bulk  of  the  particle,  depending on the concentration  of drug  incorporated.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Biodegradable nanoparticles have attracted great attention due
to their capacity not only to protect proteins and peptides from
degradation but also to desirable release profiles [1].  The devel-
opment seen in the last years in  nanotechnology and delivery
systems has been achieved mainly through new formulations with
improved stability and drug encapsulation efficiency, optimised
particle size and specific targeting [2].
Nanoparticles are very important vehicles due to their
unique features such as  their surface to mass ratio, quan-
tum properties, and potential for absorbing and carrying other
molecules [3].  Therefore the search for the appropriate carriers is
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growing. They must meet several requirements like the ability
to incorporate and release the compounds of interest, increased
formulation stability and biocompatibility. In addition, the pos-
sible adverse effect of  residual materials after delivery should
be negligible [3].  Chitosan is composed of 2-amino-2-dedoxy-
d-glucose and 2-acetamino-dedoxy-d-glucose units linked with
b-(1→4) bonds and it  is derived from alkaline deacetylation
of  chitin, one of  the most abundant natural polysaccharides
[1].  The properties of  chitosan depend mostly on its molecular
weight and degree of deacetylation [4]. The availability of free
amino groups confers to chitosan a net positive charge favour-
ing ionic interaction with many negatively charged polymers or
surfaces. Chitosan has  great potential for pharmaceutical appli-
cations due to its biocompatibility, biodegradability, antibacterial
activity, high charge density and mucoadhesion. The mucoad-
hesive properties arise from the molecular attractive forces due
to the electrostatic interaction between positively charged chi-
tosan and negatively charged mucosal surfaces [5,6]. Recently,
chitosan based delivery systems have been used for the improved
delivery and controlled release of  peptides, proteins, oligonu-
cleotides and plasmids [4,7]. It  was demonstrated that they
protect sensitive bioreactive macromolecules from enzymatic
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degradation in vivo and chemical degradation during storage
[8].
Various methods have been developed for the production of
chitosan nanoparticles such as ionotropic gelation, spray dry-
ing, emulsification and coacervation [5].  However, the addition of
an  anionic compound, like alginate, tripolyphosphate (TPP), car-
rageenan or polyelectrolyte, is the most common technique for the
preparation of  chitosan nanoparticles. The development of  stable
chitosan microsphere is limited by the ionic interaction between
chitosan and the anionic compound. The search for new non-toxic
and functional anionic compounds is  therefore of great interest.
In this work, sulfonated lignin was used for the first time as
a counter ion polymer to produce chitosan nanoparticles with
increased stability. Lignin is also a biodegradable polymer and its
physical and chemical properties can be modulated depending on
the  extraction technology [9]. In water, sulfonated lignin acts  as
an anionic polyelectrolyte due to sulfonate groups (SO3
−). Lig-
nosulfonates have high molecular weight and contain functional
sulfonate groups which  make them water soluble anionic polymers.
The water soluble lignosulfonates have many distinct applications.
The major use  of lignosulfonates is as dispersion agents. Lignin-
based products are also used in ceramics, in textile dyeing as
dispersants, in  pesticides, and as  binders in briquetting and animal
feed [10–12].  Moreover, the antioxidant and antimicrobial activi-
ties have extended their potential applications [11,13].
In this work, chitosan–lignosulfonate nanoparticles, ionically
crosslinked, were produced using ultrasonication. Ultrasonication
has  been broadly used for the preparation and processing of  poly-
mer  nanoparticles. This tool is particularly effective in reducing
particle size and narrowing size distributions [14]. As it  was  the
first attempt to incorporate lignosulfonates in chitosan particles, a
strong emphasis was given to  the properties of  lignosulfonates con-
taining particles. For this purpose, the particles optimised in terms
of size and polydispersity were further characterised regarding
degradation, loading efficiency, releasing properties, as well as
cytotoxicity. In addition, the antimicrobial activity was also evalu-
ated using two types of  Gram-negative bacteria and two  types of
Gram-positive bacteria.
2. Experimental
2.1. Materials
Chitosan from shrimp shells (deacetylation degree ≥75%; vis-
cosity 200 cps) was purchased from Sigma–Aldrich (St. Louis,
USA). The sulfonated lignin compounds isolated from hard-
wood (DP401: calcium lignosulfonates) were kindly supplied by
Borregaard-LignoTech (Sarpsborg, Norway). Commercial edible-
grade vegetable oil was used as  organic phase. Non-ionic
surfactants, poloxamer 407 and Tween 80, Lysozyme and RNase
A and all other chemicals were purchased from Sigma–Aldrich.
2.2. Chitosan–lignosulfonates (CS–LS) particles preparation
CS–LS particles were sonochemically produced by an adaptation
of Suslick method [15]. The formation of  particles was  processed by
incorporation of CS and LS solutions, 30  mL and 15  mL,  respectively,
in the presence of 5 mL of organic phase (vegetal oil). The high-
intensity ultrasonic probe was positioned at the aqueous–organic
interface and several reaction factors were considered and evalu-
ated.
2.2.1. Effect of pH of chitosan (CS) and lignosulfonates (LS)
solutions
Solutions containing 2 g  L−1 of chitosan were prepared in 1%
acetic acid, then the pH was adjusted to  4.5, 5 and 6 using 1 M
of NaOH. After pH  adjustment, solutions were  cleared using filter
paper. The LS solutions (1 g L−1)  were prepared in  distilled water
without pH  adjustment (pH ∼ 8) and in PBS buffer (pH 7.4).
2.2.2. Effect of ultrasonication time
Ultrasonic treatments were carried out using an ultrasound
probe of 13 mm in diameter with a titanium micro-tip that was
immersed to the borderline between sample solution and oil phase
(20 kHz Sonics, 40% amplitude). Ultrasonication was  carried out at
fixed amplitude with durations of 2,  5, 8 and 10 min. During ultra-
sonication, the samples were maintained in  ice and then samples
were kept at 4 ◦C for 24 h to  complete the phases separation before
being analysed.
2.2.3. Effect of stabilising agents and their concentrations
Non-ionic surfactants, poloxamer 407 and Tween 80, were
introduced in the process of  CS solution preparation. Surfactant
concentrations of 0.05, 0.1,  0.2, 0.3, 0.4,  0.5,  1  and 1.5% (v/v) were
applied to 2 g  L−1 CS solutions. The particles were produced after
the addition of LS  (1 g  L−1) by  ultrasonication for 8 min.
2.2.4. Effect of concentrations of chitosan (CS) and
lignosulfonates (LS)
Several concentrations of  CS  and LS were used in the formulation
and their effects on particle diameters were  studied. CS–LS particles
were produced in the presence of poloxamer 407 surfactant (1%,
v/v) by ultrasonication for 8 min.
2.3. Biostability of CS  and CS–LS nanoparticles
In vitro biodegradation tests of  CS nanoparticles with and with-
out LS were monitored in the absence and presence of lysosyme, a
glycoside hydrolase enzyme, by  incubating 1 mL of  particles emul-
sion with 5 mL PBS buffer, pH  7.4 in  the presence or absence of
0.5 g L−1 lysozyme at 37 ◦C  for 1 h,  3 days and 8 days. Samples of
0.25 mL were taken and filtered with a  0.2 mm  filter in  order to
remove intact particles from the hydrolysis products. The degraded
chitosan was  determined in the filtrate using the ninhydrin test.
The degradation of nanoparticles was quantitatively evaluated as
the  amount of hydrolysed chitosan leached from  the nanoparticles,
previously using chitosan as a standard for the calibration curve.
2.4. Evaluation of protein loading capacity (LC) and protein
incorporation
The RNase A  loaded CS–LS nanoparticles were prepared using
different quantities of  protein (final concentration of RNase in
solutions: 0.2, 0.5, 1.0 and 2.0 mg mL−1). The protein was  solu-
bilised in the 1 g L−1 LS  solution prior to sonication. The protein
incorporation was  determined through the quantification of free,
non-encapsulated RNase A. The separation of the free protein from
nanoparticles emulsion was accomplished by centrifugation using
Amicon ultra centrifugal filter (Ultra-15 MWCO  100 kDa). The pro-
tein quantification on aqueous medium was  made via the Lowry
method [16], using BSA as standard and using Sigma test kit n◦ P
5656. The LC was obtained following Eq. (1)  [17].
loading capacity (%) =
total RNase A  weight −  free RNase A weight
nanoparticles particles weight
× 100 (1)
2.5. In vitro release behaviour
CS–LS  nanoparticles loaded with different concentrations of
RNase A were incubated in PBS and in the absence and presence
of lysosyme at 37 ◦C for different periods of  time. After 30  min, 1,
2,  3,  4, 24 and 48 h  the suspensions were centrifuged using Ami-
con units. The  amount of released protein was quantified by the
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Lowry method. Protein unloaded CS–LS nanoparticles, under the
same conditions, were used as controls in  order to  correct for the
possible interference of  CS or LS.
2.6. Physicochemical characterisation of nanoparticles
The determination of  particle size and zeta potential was car-
ried out using a Zetasizer Nano Series (Malvern Instruments Inc.,
Worcester, UK) after appropriate dilution of nanoparticles using
ultrapure-grade water.
2.7. Antimicrobial activity test
The antibacterial effect of LS, CS and CS–LS particles as their abil-
ity to inhibit bacterial growth was  evaluated using a turbidimetric
method. A Gram-negative bacteria, Escherichia coli HB101, and two
Gram-positive bacteria, Staphylococcus aureus ATCC6538 and Bacil-
lus subtilis 48886 were tested. The microorganisms were grown in
Muller Hinton (MH) broth (Fluka Analytical, Buchs, Switzerland)
incubated at  37 ◦C. All the inocula were grown overnight and
diluted in MH broth till an optical absorbance of  0.01 at 600 nm.
Incubations were carried out in  a 96-wells plate at 200 rpm for
at least 390 min. The assay was  initiated by mixing 135 mL of the
diluted culture or just sterile MH  broth (blanks) and 15 mL  of the
nanoparticle suspensions. The CS, LS and CS–LS nanoparticles sus-
pensions were thoroughly washed with sterile PBS. Two controls
were performed, one with 50 mg  mL−1 ampicilin and the other
with 0.1× phosphate buffered saline (no treatment), the buffer
used to dilute the nanoparticles. The bacterial growth was  mon-
itored by  the optical density at 600 nm over  time corrected for the
background absorbance of each blank, using a SepctraMax 340 PC
spectrophotometer (Molecular devices, Sunnyvale, CA, USA). The
specific growth rate (min−1) was obtained from the exponential
phase time points for each growth curve and related to the spe-
cific growth rate (min−1)  of the control (PBS buffer). The error bars
for each data point were the standard deviation of three parallel
measurements.
2.8. Cytotoxicity evaluation of nanoparticles
For the cytotoxicity evaluation, only the CS,  LS and CS–LS
nanoparticles were further sterilised with 0.45 mm filters in  order
to avoid cell culture microbial contamination. Different dilutions of
these suspensions were prepared in complete culture medium. The
culture medium itself was used as a negative control, whereas a 30%
dimethyl sulfoxide (DMSO) solution (Sigma) prepared in culture
medium was  used as a toxic positive control.
2.8.1. Culture of human skin fibroblasts cell line (BJ-5ta)
The BJ-5ta cell line (normal human skin fibroblasts) was  main-
tained according to ATCC recommendations (4 parts Dulbecco’s
Modified Eagle’s Medium (DMEM) containing 4 mM  l-glutamine,
4.5 g L−1 glucose, 1.5 g  L−1 sodium bicarbonate, and 1  part of
Medium 199, supplemented with 10% (v/v) of  foetal bovine serum
(FBS), 1% (v/v) of penicillin/streptomycin solution and 10 mg mL−1
Hygromycin B). The cells were maintained at 37 ◦C in a humidified
atmosphere with 5% CO2.  Culture medium was  replaced every 2
days.
2.8.2. AlamarBlue assay
Cells were seeded at a  density of 10,000 cells/well on a 96-well
tissue culture polystyrene (TCPS) plates (TPP, Switzerland) the day
before experiments and then they were exposed to the particles
and incubated at 37 ◦C in a humidified atmosphere with 5% CO2.
Cells were examined at 24, 48 and 72 h for signs of  toxicity, using
AlamarBlue assay (AlamarBlue® Cell Viability Reagent, Invitrogen).
Resazurin, the active ingredient of  AlamarBlue® reagent, is a  non-
toxic, cell  permeable compound that is blue in colour and reduced
to resorufin, red colour compound, by  viable cells. AlamarBlue®
reagent was diluted in culture medium according to the manufac-
turer instructions and it was added to each well after aspirating the
culture medium containing the particles. After 4 h of  incubation at
37 ◦C the absorbance at 570 nm was measured, using 600  nm as a
reference wavelength, in  a microplate reader (Spectramax 340PC).
The  quantity of resorufin formed is  directly proportional to  the
number of viable  cells. The error bars for each data point were the
standard deviation of  three parallel measurements
3. Results and discussion
3.1. Preparation and characterisation of chitosan–lignosulfonates
(CS–LS) particles
In this study, the high intensity of ultrasound radiation was
applied as an inexpensive method to produce nanoparticles com-
prising CS and LS. The sulfonic-based lignin compound was  used
for the first time as the counter ion polymer to  react with the pos-
itively charged CS polymer. CS has a pKa of approximately 6.5 on
the  amino groups and at pH lower than 6.5, amines are  protonated
acquiring therefore a polycationic behaviour [4]. In aqueous reac-
tion medium, CS and LS strongly bond by electrostatic interactions.
The positive charge on CS gives rise to strong electronic interac-
tion with negatively charged surfaces or polymers. This allows for
the high bioavailability and biocompatibility that characterise CS.
Furthermore, the charge property, particle size, density, viscos-
ity, deacetylation degree and molecular weight are also important
factors which influence the properties and applicability of  pharma-
ceutical formulations based on  CS [5].
A detailed characterisation of CS–LS  particles was  performed.
Fig. 1A shows that each type of polymer composition present dis-
tinct particle properties. The zeta-potential values, in  particular,
demonstrate well  the electronic charge character of the particles
that is inherent to the functional groups of the polymer. The com-
bination of  both LS and CS  resulted in positively charged particles
(CS–LS: +30.85 mV)  which may be explained by an unequal phys-
ical distribution of  CS  and LS within the particle, with CS being
located predominantly on  the outer layer. The hypothetical struc-
ture of  particles produced by  ionic interaction between CS and LS
is schematically presented in Fig. 1B.
The physical stability and in vivo distribution of  nanoparticles
are  affected by  their mean size, polydispersity and surface charge
[14]. Aiming at particle smaller sizes and narrower size distribu-
tions, the influence of  various reaction parameters were studied, in
particular, the pH  of CS solutions and the duration of ultrasonica-
tion.
The size of  particles is very important for an  efficient applicabil-
ity. When particle size is smaller, nanoparticles have larger surface
to volume ratio with a more controlled release of insoluble drugs
[5].  The pH of  CS was adjusted to  4.5,  5  and 6  using  1 M  of NaOH
and several sonication periods were tested. By observing Fig. 2, both
factors seem to be determinant factors in the preparations of CS–LS
particles. Tang et  al. have reported that the ultrasonication led to a
decrease in mean diameter and polydispersity of  particle size when
the duration time or amplitude was increased [14]. According to the
results (Fig. 2), a concomitant decrease of  particle size and poly-
dispersity is also observed with increasing sonication time. Eight
minutes are sufficient to produce smaller and less polydisperse
nanoparticles. This was the time chosen to produce the CS–LS par-
ticles for further testing. A range of pH values of  CS solutions were
also studied in  parallel. The pH is determinant in the formation of
CS and LS complexes, since it  establishes the CS protonation degree
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Fig. 1. (A) Average diameter, polydispersity and zeta potential of CS, LS and CS–LS particles, produced by ultrasonication for 8 min before further optimisation. (B) Scheme
of  CS–LS particles formation based on  ionic interactions between NH3
+ groups of  CS and SO3
− groups of LS.
and therefore the ability of CS to interact with the counter ions and
its self-association [7]. When the pH of CS solution is not adjusted
(pH values around 3.5), the sizes  of  particles are  highly dispersed
(Fig. 2B). Adjusting the pH of CS  to 5  was the best condition for
CS–LS particle formation for both smaller particles’ diameter and
lower polydispersity. Duration of sonication does not  influence par-
ticle charge (Fig. 2C).  The zeta potential is, however, highly affected
by the pH of CS  solutions used for particle production. As expected,
the surface charge of particles negatively correlated with pH  values
of  initial solutions (Fig. 2C). The use  of  PBS buffer to  solubilise LS
affected the particle size distribution but not the average particles’
diameter (Fig. 2A and B). A much lower zeta potential was obtained
when PBS was used as solvent comparing to distilled water  for the
preparation of LS (Fig. 2C).
After achieving the optimum conditions for CS–LS particles pro-
duction, the effect of a stabiliser agent and the concentration of CS
and LS were studied. Non-ionic surfactants (poloxamer 407 and
Tween 80) which are commonly used for food, medical and cos-
metic applications were tested. They exhibited different effects on
particles’ size. With poloxamer, the diameter decreased sharply
with the increase of  surfactant amount in the reaction medium till
0.2% (v/v) (Fig. 3A). From 0.2 to 1%  added poloxamer, the reduction
in  particle size was less prominent, while size increased in pres-
ence of more than 1% poloxamer. The polydispersity also reaches a
minimum at 1%  (v/v) of poloxamer concentration. The addition of
another surfactant, Tween 80,  did not produce coherent results and
the particle size as well as the polydispersity values  were too high
when compared with those obtained using poloxamer (Fig. 3B).
This result shows that poloxamer was  more efficient than Tween
80 in decreasing CS–LS particle size and polydispersity.
After optimising the pH, sonication time and surfactant for par-
ticles production, the effects of  CS and LS concentrations were also
studied. The concentration of  chitosan did not affect significantly
the average particle diameter. At 10 g L−1 of chitosan solution,
though the smallest size and the lowest polydispersity of  CS–LS
nanoparticles (size:  221 nm,  polydispersity: 0.15) were obtained,
the  high viscosity was a  major drawback in the mixing procedure.
Considering the results, to test the influence of  LS concentration,
2 g  L−1 chitosan was the chosen CS concentration (size: 226  nm,
polydispersity: 0.21). The best chitosan/lignosulfonates ratio found
was 2:1  corroborating previous results made obtained this ratio
(Fig. 4A and B).
Nanoparticles’ chemical composition, size, shape, surface
charge, hydrophobicity [18]  and the presence or absence of func-
tional groups or other chemicals [19] are important characteristics
that will define their potential application. Nanoparticles are
widely applied on  medical and cosmetic areas for drug delivery
purposes. In medical application, if  orally and intravenously admin-
istrated, the optimal size of nanoparticles should range from 10
to 200 nm. The micrometre size below 200 allows for systematic
administration in circulation system and also into targeted tissue
as well as enhance the ability of  nanoparticles to  evade the biolog-
ical particulate filters, such as the reticuloendothelial system [20].
On the other hand, for cosmetic applications, e.g. topically applied
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Fig. 2. Influence of solutions pH  and  ultrasonication time on the  mean particles
diameter (A), polydispersity (B) and  of zeta-potential (C)  of CS–LS particles. The pH
values that appear in the  legend are the pH for the CS  solutions; no pH control means
that the pH of CS solution was not adjusted. The LS solution was prepared in  water
except for the assay pH  5 LS (PBS), this curve was obtained when the LS solution
was  prepared in PBS pH 7.4.
on skin, sizes above 200 nm can  be successfully used. Despite the
fact that evidences have been showing that  nanoparticles > 10 nm
in diameter are  unlikely to penetrate through the stratum corneum
into viable human skin, they are able to accumulate in the hair
follicle openings, especially after massage [21].
After the optimisation process, the CS–LS particles were char-
acterised with an average particle size of 230 nm, which  constitute
a suitable carrier for being applied topically on  the skin, e.g. for
cosmetic applications.
3.2. CS–LS nanoparticles biostability
The degradation profile of  CS–LS nanoparticles was tested in the
presence of either PBS or lysozyme, a mammalian enzyme present
in healthy human secretions [22,23] that is capable of degrading
chitosan [7].  Fig. 5A shows the chitosan degradation profile of  CS
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Fig. 3. Mean particles diameter and polydispersity of CS–LS nanoparticles as a func-
tion of concentration of  poloxamer 407 (A)  and  Tween 80  (B) surfactant.
and CS–LS nanoparticles after 1 h, 3 days and 8 days of  incubation.
The nanoparticles were considered stable after 1 h and 3 days of
incubation in either PBS or lysozyme (Fig. 5A). However, the sta-
bility of  CS nanoparticles was clearly diminished after 8  days of
incubation, in particular in  the presence of  lysozyme. CS–LS parti-
cles were even more susceptible to lysozyme activity for the same
period. It has been  reported that the stability of  CS complexes with
anionic polyelectrolyte depends mainly on the degree of ionisation
of each of  the oppositely charged polyelectrolytes [24].  Complexes
are stabilised by different types of intermolecular bonds, ionic,
covalent, van der Walls interactions and hydrogen bonding [25].
The type and  strength of the bonds determine the different degra-
dation profiles.
The incorporation of lignosulfonates in  CS particles seems to
favour the degradation of  chitosan in  the presence of  lysozyme and
it does not affect the stability in PBS. These results indicate that
these nanoparticles are potential candidates for drug delivery car-
riers since they are  stable under physiological conditions, and they
can be further tuned for drug release.
3.3. Entrapment and release behaviour of RNase A in CS–LS
nanoparticles
Chitosan has been extensively investigated for the develop-
ment of  novel drug delivery nanosystems. There are many factors
affecting the entrapment efficiency of drugs or proteins  into
nanoparticles. The chemical nature of  the drug, the ratio of  drug
to chitosan in the formulation and the stirring speed (mechan-
ical energy applied) are some examples. These parameters also
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Fig. 4.  Mean particles diameter and polydispersity of CS–LS microspheres as  a func-
tion of concentration of  chitosan (A)  and lignosulfonates (B).
determine the drug release behaviour from chitosan nanoparti-
cles. Apart from this, the type  and concentration of the crosslinking
agent, the type of oil,  additives (surfactant or emulsifier) and the
molecular weight of chitosan are also important players in the con-
trolled release of the drug [5].
In this work, to  study the entrapment efficiency of  the newly
developed CS–LS nanoparticles, RNase A  was used as a model pro-
tein. Various RNase A concentrations were tested (Table 1). The
results indicate that the higher the concentration of initial RNase
A solution the higher is the protein incorporation and loading
capacity. Both size and polydispersity of particles increase with
increasing RNase A entrapment into chitosan nanoparticles.
Table 1
Protein incorporation, loading capacity, average diameter and polydispersity of
CS–LS nanoparticles loaded with  different concentrations of  RNase A.
Rnase A  load
(g L−1)
Entrapped
protein (g L−1)
Loading
capacity (%)
Size (nm) Polydispersity
0  –  – 236.9  ± 6.5 0.17 ± 0.03
0.2  0.122 6.6 273.1  ± 12.1  0.22 ± 0.07
0.5  0.222 11.9  304.1 ± 8.0  0.30 ± 0.05
1.0 0.274 14.7  471.5  ± 21.5  0.62 ± 0.06
2.0 0.800 43.0  481.1  ± 43.2  0.63 ± 0.07
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Fig. 5.  (A)  Stability of  CS and CS–LS nanoparticles incubated in  PBS or lysozyme
for  1 h, 3 days or  8 days. (B) Releasing profile of RNase A protein from the  CS–LS
nanoparticles in  the presence of  0.5  g L−1 lysozyme (solid lines) or in  the absence of
lysozyme (just PBS buffer, dashed lines).
The mechanism of drug molecules entrapment in nanoparti-
cles is an important aspect to be determined. The drugs either
bind to the surface or are  encapsulated inside the nanoparticles.
The ultrasound-induced nanoparticles, however, may incorporate
load in both ways. The ultrasound technique is known to  gener-
ate aqueous suspensions of biopolymer microcapsules filled with
water-insoluble liquids [26].  Therefore, if the drug is liposoluble it
will be encapsulated inside the nanoparticle while if the drug is
water soluble it  will remain at the aqueous–lipid interface.
In Fig. 5B, the releasing profiles of  CS–LS nanoparticles loaded
with either the lowest (0.2 g  L−1)  or the highest concentration
(2 g L−1)  of RNase A are  depicted. A burst release was observed in
the initial 4 h of  incubation after which the protein release sta-
bilised under all the conditions tested (Fig. 5B). The amount of
RNase released from the particle loaded with 0.2 g L−1 RNase A  was
superior, approximately 100% when exposed to both lysozyme and
PBS in comparison to the amount released from the particle loaded
with the higher concentration of  protein (around 50% in the pres-
ence of lysozyme and 5%  in  PBS). These profiles may indicate that
the entrapment mechanism is  dependent on the drug concentra-
tion. At lower protein concentrations the entrapment at the surface
of nanoparticles may  be favoured, while at higher concentrations
both surface and bulk protein entrapment may  occur, explain-
ing both the polydispersity of particles (Table 1)  and the release
behaviour observed with both concentrations (Fig. 5B). An alterna-
tive explanation can be the difference in surface area available for
the lysozyme action. The surface area is higher for the lowest pro-
tein loads (the average diameter is lower), therefore more  surface
is available to the action of this enzyme.
Despite the fact that the fast release of  a drug in a  burst stage
can be pharmacologically dangerous and economically inefficient
[27], there are  certain situations where the rapid release or high
S.  Kim et  al. / Colloids and Surfaces B:  Biointerfaces 103 (2013) 1– 8 7
Fig. 6. Antimicrobial effect of CS, LS and CS–LS nanoparticles evaluated as the rela-
tive decrease in specific growth rate of  each microorganism.
initial rates  of delivery may be desirable. In cosmetic applica-
tions, the burst release is desired because it  improves the drug
penetration into the skin [28]. Other examples include wound man-
agement, encapsulation of flavours, triggered burst release and
pulsatile release [27].
3.4. Particles antimicrobial activity
Fig. 6 shows the relative specific growth rates obtained for a
Gram-negative bacteria E. coli, and for two Gram-positive bacte-
ria S. aureus and B.  subtilis when in  contact with these particles.
The specific growth rate obtained for each microorganism grown in
MH medium containing the nanoparticles suspensions, was  com-
pared to the specific growth rates when the microorganism was
simply grown in MH  medium (no treatment). When microorgan-
isms were grown in MH  medium containing 100 mg mL−1 ampicilin,
the culture absorbance did not change over time (data not shown).
The growth rates of  all tested microorganisms were decreased
by exposure to all three types of nanoparticles. The concentra-
tion of CS, LS CS–LS in MH  medium was 5 ×  1010,  5 × 1010 and
3 × 1010 particles/mL, respectively, as determined by Nanoparticle
Tracking Analysis.
Chitosan has long been known for its antimicrobial activity,
although only recently nanoscaled chitosan and its derivatives have
been characterised as antimicrobial agents against bacteria, viruses
and fungi [29–32].  In relation to  bacteria, the antimicrobial activity
of chitosan has  been reported to be  higher against Gram-positive
compared to Gram-negative bacteria [31]. Several antimicrobial
mechanisms have been proposed for chitosan [29,31]. One mech-
anism involves positively charged chitosan particles interacting
with negatively charged cell membranes, causing an  increase in
membrane permeability and eventually rupture and leakage of
intracellular components [29].  This mechanism could explain the
antimicrobial effect of CS and CS–LS nanoparticles, since they both
have a positive zeta potential.
Comparing the growth rates between the Gram-negative and
the Gram-positive bacteria, it  appears that Gram-positives are also
more susceptible to LS nanoparticles (Fig. 6). To our knowledge, this
is  the first report demonstrating the bacteriostatic activity of  ligno-
sulfonates. Whether the composition of the cell wall or other factors
specific to these bacteria could be associated with the activity of
this compound is not  yet known. Since the charge of LS particles is
negative, the mechanism must  be different from the one that could
explain the action of CS-containing nanoparticles.
Another interesting result was the fact that lignosulfonates and
chitosan combined together in  a particle have an enhanced antimi-
crobial effect against E. coli and B.  subtilis.  It is reasonable to suspect
that the enhanced antimicrobial effect is due to the particular prop-
erties of CS–LS particles: high positive charge (around +31 mV)  and
high surface area (average diameter 226 nm).
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Fig. 7. Viability of human normal skin fibroblast cell  line, BJ-5ta, after contact with
sterilised suspensions of CS, LS and CS–LS nanoparticles during 24,  48 and 72 h. The
viability is  obtained by  comparison with the negative control (no treatment).
3.5. Particles cytotoxicity
The  biocompatibility of  chitosan, lignosulfonates and
chitosan–lignosulfonates particles was assessed on a human
normal skin fibroblast cell line using AlamarBlue® assay, a simple
and rapid method used to estimate the cytotoxicity of  chemicals
on cultured cells. Resazurin is reduced by cellular reductases to
a pink-coloured chromophore, which is a  direct measure of cell
viability [33].  The nanoparticles suspensions of  CS, LS and CS–LS,
were found to  be non-toxic after 72  h of  exposure (Fig. 7). A slight
toxicity was  observed when cells where incubated with particles
containing lignosulfonates after 24 h of  incubation but were
capable of  recovery (Fig. 7). In fact, the recovery of fibroblasts from
cytotoxic effects has  been reported for lipid-based microparticles
[34]. This behaviour indicates that CS–LS carriers are eventually
biocompatible and can be safely applied to human skin.
4. Conclusions
Sonochemically prepared CS–LS nanoparticles were developed
in this study as a  potential carrier for drug delivery systems for
both cosmetic and biomedical applications. A full characterisation
of these particles was performed and after an optimisation process
we were able to determine the conditions to attain carriers smaller
than 230 nm in diameter. The electrostatic interactions between CS
and LS were found to be determinant to develop biostable CS–LS
nanoparticles, when compared with CS nanoparticles alone, which
were found to be non-toxic and biocompatible and, furthermore,
with increased antimicrobial activity. Apart from  this, the CS–LS
nanoparticles were found to  display controlled release properties,
depending on the amount of the incorporated protein model.
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